PREGENE x KITE: Kite double-downs on its in vivo CAR-T arsenal. Read More »
Just last month, Kite Pharma’s announced a $1.64B collaboration ($120M upfront + up to $1.52 billion in milestone payments) with Pregene to co-develop the next-generation of in vivo CAR-T therapies.
Genmab acquires Merus to strengthen its antibody-based clinical portfolio Read More »
Genmab acquires Merus in a complete buy-out $8 billion deal to further strengthen its antibody-based late clinical programs portfolio.
Jonas Schwickert, PhD – DISCOVER Trainee Management Human Pharma Operations Read More »
Jonas is a former PhD student in the field of cancer reserach who transitioned 2 years ago into industry, where he started his career as a Management Trainee Human Pharma at Boehringer Ingelheim
Wugen´s agent WU-CART-007: a soldier against T-cell cancers Read More »
Wugen is a US-born and based biotech that develops off-the-shelf allogeneic CAR-T therapies to treat hematological malignancies. In particular, Wugen
Updates in Hematology Read More »
Weekly selection of scientific articles exploring the involvement of the bone marrow microenvironment in disease progression and therapy resistance
Kite (a Gilead company) joins the in vivo CAR-T race Read More »
Kite (a @Gilead company) announced the complete buyout of Interius BioTherapeutics, a biotech company developing in vivo CAR-T and NK cell reprogramming platforms, for $350 million USD in cash.
AbbVie Bets $2.1B on in vivo CAR-T: What makes Capstan Therapeutic special? Read More »
Last June, Abbvie confirmed the acquisition of Capstan Therapeutics for 2.1bn USD cash. Given the recent amount and volume of
Updates in Hematology Read More »
Weekly selection of scientific articles exploring application of stem cells across multiple areas.
From Poison to Precision: Harnessing Amanitin for Next-Gen Cancer Therapies Read More »
Have a look at how a german Biotech company has leveraged the poisonous Amanitin compound to develop anti-cancer therapies.
Updates in Hematology Read More »
Weekly selection of scientific articles in the field of Hematology focusing on prognostic values and novel therapeutics in hematological malignancies